Primary and urgent care group Med First has reported an increase of more than 6% in revenue after it started implementing ‍Arintra’s medical coding solutions. Serving more than 220,000 patients each year, the group implemented the autonomous coding solutions through the athenahealth Marketplace. The AI medical coding enhancement underpins Med First's strategy to increase its number of locations from 27 to nearly 40, with the goal of improving access to healthcare services. With a limited number of certi ...

MIAMI BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report third quarter 2025 financial results before market open on Friday, November 7, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conferen ...

财报发布信息 - 公司计划于2025年11月3日开盘前公布2025年第三季度财报 [1] - 第三季度每股收益（EPS）的Zacks共识预期为0.46美元，营收预期为4.841亿美元 [1] 第三季度业绩预期 - 第三季度每股收益预期同比增长4.6%，但营收预期同比下降5.3% [2] - 第三季度净患者服务收入模型预期同比下降7.4% [9] - 第三季度医院合同管理费模型预期同比下降5.7% [9] - 同机构营收增长共识预期为3.35%，其中同机构患者量增长1.3%，净报销增长2.05% [10] - 同机构新生儿重症监护病房（NICU）患者天数增长共识预期为4% [10] 2025年全年业绩预期 - 2025年全年营收共识预期为18.9亿美元，同比下降6% [3] - 2025年全年每股收益共识预期为1.78美元，同比增长17.9% [3] 盈利预测趋势与历史表现 - 过去60天内，第三季度每股收益预期保持稳定，修订趋势为0% [3] - 公司在过去四个季度均超出盈利预期，平均超出幅度达28.7% [4] 成本与费用预期 - 总运营费用模型预期同比下降近11%，主要得益于薪资福利、物料及其他费用以及管理费用的降低 [11] - 较低的运营费用，包括薪资和管理费用，可能有助于提升公司利润 [8] - 第三季度利息费用模型预期超过900万美元，预计将继续同比下降 [11] 现金流预期 - 第三季度经营现金流模型预期约为1.21亿美元，较去年同期显著增长 [11] 同业公司业绩比较 - HCA Healthcare第三季度调整后每股收益6.96美元，超出共识预期23.2%，同比增长42% [13] - Universal Health Services第三季度调整后每股收益5.69美元，超出共识预期22.1%，同比增长53.4% [14] - Community Health Systems第三季度调整后每股收益1.27美元，远超共识预期的亏损0.32美元，去年同期为亏损0.30美元 [15]

核心财务表现 - 第三季度调整后每股收益为1.60美元，同比增长46.8%，超出市场预期17.65% [1] - 第三季度总收入为1028.7亿美元，同比增长7.8%，超出市场预期4.66% [2] - 按美国通用会计准则计算，公司录得每股亏损3.13美元，而去年同期为每股收益0.07美元 [1] 各业务部门收入 - 健康服务业务收入为492.7亿美元，同比增长11.6%，主要受药品组合和品牌药价格上涨推动 [3] - 药房与消费者健康业务收入为362.1亿美元，同比增长11.7%，主要受药品组合和处方量增加推动 [4] - 健康保险业务收入为360亿美元，同比增长9.1%，主要受政府业务增长推动，特别是《通胀削减法案》对医疗保险D部分的影响 [4] - 按30天等效基础计算，处理的处方总量同比下降1.8% [3] 盈利能力与成本 - 第三季度总销售产品成本增长7.7%至570.5亿美元，毛利润增长7.9%至458.3亿美元 [5] - 毛利率扩大3个基点至44.6%，调整后运营利润率扩大12个基点至33.6% [5] - 总运营费用增长6.9%至112.9亿美元 [5] 资产负债与现金流 - 第三季度末现金及现金等价物为91亿美元，低于第二季度末的117.9亿美元 [6] - 长期债务为605.1亿美元，高于上一季度的572.9亿美元 [6] - 第三季度末累计经营活动提供的净现金为72.5亿美元，与去年同期基本持平 [6] 业绩展望 - 公司将2025年调整后每股收益指引上调至6.55-6.65美元，此前指引为6.30-6.40美元 [8][9] - 当前市场对2025年调整后每股收益的共识预期为6.36美元 [9] 业务驱动因素 - 药房与消费者健康业务的增量销量由收购Rite Aid处方档案所驱动 [10] - 公司的药品福利管理机构Caremark在销售季保持了超过90%的客户留存率 [10]

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +12.50%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.07, delivering a surprise of +16.67%.Over the last four quarters, the company ...

季度业绩表现 - 季度每股收益为160美元，超出市场预期的136美元，较去年同期109美元增长468% [1] - 季度营收达10287亿美元，超出市场预期466%，较去年同期9543亿美元增长78% [2] - 本季度盈利超出预期1765%，上一季度盈利超出预期2313% [1] - 公司在过去四个季度均超出每股收益和营收预期 [2] 股价表现与市场对比 - 公司股价年初至今上涨831%，同期标普500指数上涨172% [3] - 股价近期走势的可持续性将取决于管理层在财报电话会中的评论 [3] 未来业绩展望 - 当前市场对下一季度的共识预期为每股收益095美元，营收10048亿美元 [7] - 当前财年共识预期为每股收益636美元，营收39228亿美元 [7] - 财报发布前，业绩预期修订趋势好坏参半，当前Zacks评级为3级（持有） [6] 行业表现与同业对比 - 公司所属的医疗服务业在Zacks行业排名中位列前39% [8] - 同业公司Sera Prognostics预计季度每股亏损019美元，同比改善208% [9] - Sera Prognostics预计季度营收7万美元，较去年同期增长1167% [9]

UPPSALA, SE / ACCESS Newswire / October 29, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB's (publ) interim report for January - September 2025 is now available on the company's website www.senzime.com . Strategic events during and after the end of the third quarter Additional strategic hospital contracts secured in the U.S. market. ...

Key Takeaways Ecolab reported Q3 adjusted EPS of $2.07, beating estimates and rising from the prior-year quarter.Ecolab's Q3 revenue reached $4.17B, supported by organic growth across Water, Pest and Life Sciences.Ecolab expanded gross and operating margins, reflecting improved profitability across its segments.Ecolab Inc. (ECL) has reported third-quarter 2025 adjusted earnings per share (EPS) of $2.07, up 13.1% year over year. The bottom line surpassed the Zacks Consensus Estimate by a penny.GAAP EPS for t ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is HCA Healthcare (HCA) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.HCA Healthcare is a member of the Medical sector. This group includes 955 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual st ...

Shares of HCA Healthcare (HCA) have been strong performers lately, with the stock up 11.2% over the past month. The stock hit a new 52-week high of $469.18 in the previous session. HCA has gained 55.9% since the start of the year compared to the 2.6% move for the Zacks Medical sector and the 7% return for the Zacks Medical Services industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last fo ...